Guldane Cengiz Seval

List of Publications by Year
in descending order

115 papers	4,551 citations	218677 26 h-index	110387 64 g-index
118 all docs	118 docs citations	118 times ranked	4556 citing authors

#	Article	IF	Citations
1	SARS-CoV-2 Mutations and their Viral Variants. Cytokine and Growth Factor Reviews, 2022, 63, 10-22.	7.2	113
2	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncology, The, 2022, 23, 416-427.	10.7	54
3	Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?. Frontiers in Oncology, 2022, 12, 800711.	2.8	3
4	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplantation and Cellular Therapy, 2022, 28, 284-293.	1.2	11
5	Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020â€"Report from World Marrow Donor Association. Bone Marrow Transplantation, 2022, 57, 1021-1024.	2.4	7
6	When a Monoclonal Gammopathy Is Not Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 655-664.	3.8	2
7	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. Blood Advances, 2022, 6, 3870-3874.	5.2	8
8	Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 67-75.	0.6	8
9	Efficacy and safety of weekly carfilzomib (70â€‰mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leukemia and Lymphoma, 2021, 62, 358-367.	1.3	13
10	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2021, 35, 31-44.	7.2	79
11	Suppression of steroid 5Î±-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. Cell Death and Disease, 2021, 12, 206.	6.3	13
12	A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT. Turkish Journal of Haematology, 2021, 38, 69-71.	0.5	1
13	Expert review on softâ€tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	2.5	67
14	Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e267-e271.	0.4	1
15	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
16	HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. Journal of Hematology and Oncology, 2021, 14, 54.	17.0	75
17	Rosaiâ€Dorfman disease presenting with nasal, nodal and multiple cutaneous involvements responding to a combination of systemic steroid and lowâ€dose thalidomide therapy. Dermatologic Therapy, 2021, 34, e14988.	1.7	0
18	Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors. Turkish Journal of Haematology, 2021, 38, 111-118.	0.5	0

#	Article	IF	Citations
19	Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or Without Aplastic Anemia: Multicenter Turkish Experience. Turkish Journal of Haematology, 2021, 38, 195-203.	0.5	0
20	CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Molecular Cancer, 2021, 20, 84.	19.2	33
21	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 801-812.	10.7	162
22	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58.	27.0	268
23	Host variations in SARS-CoV-2 infection. Turkish Journal of Biology, 2021, 45, 404-424.	0.8	2
24	Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience. LLM Dergi, 2021, 5, 1-4.	0.0	0
25	Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. Journal of Clinical Medicine, 2021, 10, 3940.	2.4	10
26	Allogeneic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: A Single Center Experience. LLM Dergi, 2021, 5, 16-20.	0.0	0
27	A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity. Immunogenetics, 2021, 73, 449-458.	2.4	5
28	The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation. Journal of Ankara University Faculty of Medicine, 2021, 74, 337-342.	0.1	0
29	Treatment approaches for managing patients with hematological malignancies in the time of COVID-19 pandemic. Turkish Journal of Medical Sciences, 2021, , .	0.9	0
30	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
31	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology,the, 2021, 8, e934-e946.	4.6	46
32	Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study. Blood, 2021, 138, 2747-2747.	1.4	1
33	Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE). Blood, 2021, 138, 3045-3045.	1.4	0
34	A Bottom-Up Proteomic Approach in Bone Marrow Plasma Cells of Newly Diagnosed Multiple Myeloma Patients. Current Proteomics, 2021, 18, 730-741.	0.3	0
35	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica, 2020, 105, 201-208.	3.5	48
36	Fetal Cell Microchimerism; Normal and Immunocompromised Gestations in Mice. Fetal and Pediatric Pathology, 2020, 39, 277-287.	0.7	3

#	Article	IF	Citations
37	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology, 2020, 38, 4030-4041.	1.6	56
38	KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells. Biology of Blood and Marrow Transplantation, 2020, 26, S315.	2.0	0
39	Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data. Biology of Blood and Marrow Transplantation, 2020, 26, S305-S306.	2.0	0
40	Prognostic scoring system after transplantation in myeloma: predicting early relapse. British Journal of Haematology, 2020, 191, 323-324.	2.5	1
41	Isatuximab for the treatment of relapsed/refractory multiple myeloma. Expert Opinion on Biological Therapy, 2020, 20, 1395-1404.	3.1	22
42	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood, 2020, 136, 3033-3040.	1.4	146
43	Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma. Frontiers in Oncology, 2020, 10, 767.	2.8	16
44	Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e474-e484.	0.4	7
45	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of Hematology, 2020, 99, 1793-1804.	1.8	4
46	Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, S109-S110.	2.0	0
47	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia, 2020, 34, 1840-1852.	7.2	55
48	Ibrutinib As a Promising Treatment for Pulmonary Complications Due to Refractory Chronic Graft Versus Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, S191.	2.0	1
49	Drug Targeting of Genomic Instability in Multiple Myeloma. Frontiers in Genetics, 2020, 11, 228.	2.3	12
50	Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95). Blood, 2020, 136, 46-48.	1.4	4
51	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. Blood, 2020, 136, 4-6.	1.4	3
52	Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis. LLM Dergi, 2020, 4, 23-27.	0.0	0
53	First Turkey Experience of 11C-Methionine PET in Multiple Myeloma. Turkish Journal of Haematology, 2020, , .	0.5	0
54	Relapse of Immune Thrombocytopenic Purpura in a Patient With COVID-19. Infectious Diseases and Clinical Microbiology, 2020, 2, 184-186.	0.3	0

#	Article	IF	Citations
55	The natural course of non-alcoholic fatty liver disease. Hepatology Forum, 2020, , 20-24.	0.5	4
56	The Outcomes of Splenectomy and Drug Therapy in Patients with Splenic Marginal Zone Lymphoma. LLM Dergi, 2020, 4, 10-13.	0.0	0
57	Bir Nakil Merkezinin 11 YÄ±llÄ±k Allojeneik KÃ¶k HÃ¼cre Nakli Deneyimi. LLM Dergi, 2020, 4, 50-54.	0.0	0
58	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leukemia and Lymphoma, 2019, 60, 163-171.	1.3	11
59	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2019, 394, 2096-2107.	13.7	435
60	Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable â‰¥Vgpr Responses Among Immunomodulatory / Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e242-e243.	0.4	1
61	Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. Turkish Journal of Gastroenterology, 2019, 30, 122-131.	1.1	3
62	A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma. Expert Opinion on Drug Safety, 2019, 18, 563-571.	2.4	25
63	PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma. PET Clinics, 2019, 14, 369-381.	3.0	9
64	Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e197.	0.4	0
65	A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis. Leukemia and Lymphoma, 2019, 60, 151-162.	1.3	8
66	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
67	Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1521-1530.	1.7	4
68	Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies. Clinical Hematology International, 2019, 1, 134-141.	1.7	2
69	Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?. Journal of Clinical Oncology, 2019, 37, e19524-e19524.	1.6	0
70	Impact of Hepatitis B Core Antibody Seropositivity on the Liver Function Tests After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. LLM Dergi, 2019, 3, 55-59.	0.0	0
71	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	7.2	68
72	Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. Annals of Hematology, 2018, 97, 1027-1039.	1.8	19

#	Article	IF	Citations
73	Comparing Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S306.	0.4	1
74	Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, S142.	2.0	0
75	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e401-e419.	0.4	61
76	The safety of bortezomib for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 2018, 17, 953-962.	2.4	64
77	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Blood, 2018, 132, 301-301.	1.4	9
78	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). Blood, 2018, 132, 1994-1994.	1.4	10
79	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. Blood, 2018, 132, 3186-3186.	1.4	3
80	Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation. Balkan Medical Journal, 2018, 35, 131-140.	0.8	12
81	Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience. Blood, 2018, 132, 5331-5331.	1.4	0
82	KIR 2DS4 May Influence Autologous and Cord Blood(CB) Natural Killer (NK)Cell Mediated in Vitro Cytotoxicity Against Freshly Isolated Human Bone Marrow Myeloma Plasma Cells and Cell Lines. Blood, 2018, 132, 1920-1920.	1.4	0
83	Residual Clonal Plasma Cells Detected By Flow Cytometry at 10-4level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival. Blood, 2018, 132, 3438-3438.	1.4	0
84	Is the End Close for the Graft-Versus-Host Disease That Is a Big Problem Following Allogeneic Hematopoetic Stem Cell Transplantation?. Blood, 2018, 132, 5729-5729.	1.4	0
85	Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. Blood, 2018, 132, 4673-4673.	1.4	0
86	Effects of singleâ€agent bortezomib as postâ€transplant consolidation therapy on multiple myelomaâ€related bone disease: a randomized phase <scp>II</scp> study. British Journal of Haematology, 2017, 178, 61-71.	2.5	12
87	Phase 2 study of tabalumab, a human antiâ€Bâ€cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. British Journal of Haematology, 2017, 176, 783-795.	2.5	39
88	Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model. Turkish Journal of Haematology, 2017, 34, 137-142.	0.5	4
89	Editorial: â€œHow to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment?â€. Frontiers in Medicine, 2016, 3, 20.	2.6	0
90	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 754-766.	27.0	1,246

#	Article	IF	Citations
91	Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients. Journal of Clinical Medicine, 2015, 4, 441-459.	2.4	17
92	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica, 2015, 100, 1254-1266.	3.5	289
93	Impact of â€œKiller Immunoglobulin-Like Receptor /Ligandâ€•Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival. PLoS ONE, 2015, 10, e0132526.	2.5	19
94	Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report. Turkish Journal of Haematology, 2015, 32, 180-183.	0.5	4
95	Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice. Blood, 2015, 126, 3034-3034.	1.4	1
96	ERRATUM. Methods in Molecular Biology, 2014, 1109, E1-E2.	0.9	0
97	Blood donors and factors impacting the blood donation decision: Motives for donating blood in Turkish sample. Transfusion and Apheresis Science, 2013, 49, 468-473.	1.0	37
98	Preliminary Results Of A Mass Spectrometry Based Bottom Up Proteomic Approach On Bone Marrow Plasma Cells From Patients With Multiple Myeloma (MM). Blood, 2013, 122, 1887-1887.	1.4	2
99	Comparison Of Flow Cytometric and Clinical Findings In Patients With Paroxysmal Nocturnal Hemoglobinuria. Blood, 2013, 122, 4877-4877.	1.4	0
100	Flowcytometric evaluation of cell cycle regulators (cyclins and cyclin dependent kinase inhibitors) expressed on bone marrow cells of patients with chronic myelogenous leukemia and multiple myeloma. Turkish Journal of Haematology, 2012, 29, 17-27.	0.5	1
101	Role of Killer Immunoglobulin-Like Receptor and Ligand Matching in Donor Selection. Bone Marrow Research, 2012, 2012, 1-6.	1.7	11
102	Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells. Stem Cell Reviews and Reports, 2012, 8, 953-962.	5.6	30
103	Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. European Journal of Haematology, 2011, 86, 16-22.	2.2	133
104	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) â‰¥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65â€“75 Yrs Enrolled in MM-015. Blood, 2011, 118, 475-475.	1.4	12
105	Immunophenotyping Features in Acute Myeloid Leukemia (AML) with NPM1+ and/or FLT3+. Blood, 2011, 118, 4908-4908.	1.4	0
106	Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.. Blood, 2009, 114, 52-52.	1.4	15
107	Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.. Blood, 2009, 114, 4846-4846.	1.4	0
108	The evolving treatment paradigm of multiple myeloma: From past to present and future. Turkish Journal of Haematology, 2008, 25, 60-70.	0.5	0

#	Article	IF	Citations
109	Pyrimidine 5â€² Nucleotidase-1 (P5N-1) Deficiency Associated with 4 Novel Mutations in 5 New Turkish Families: Genotype-Phenotype Analysis.. Blood, 2006, 108, 3743-3743.	1.4	0
110	A New Predictive and Prognostic Marker for De Novo AML: Peripheral Blood CD34 (pCD34) Count at Recovery Following Remission Induction (RI) Therapy (Supp. by Ankara University-2003-0809114).. Blood, 2005, 106, 4517-4517.	1.4	0
111	The Impact of Methylenetetrahydrofolate Reductase C677T Gene Polymorphism on Engraftment after Allogeneic Hematopoietic Cell Transplantation.. Blood, 2005, 106, 5318-5318.	1.4	0
112	Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-?-2a treatment. Cancer, 2000, 89, 1474-1481.	4.1	9
113	Circulating CD44 and intercellular adhesion moleculeâ€1 levels in low grade nonâ€Hodgkin lymphoma and Bâ€cell chronic lymphocytic leukemia patients during interferonâ€±â€2a treatment. Cancer, 2000, 89, 1474-1481.	4.1	1
114	Randomised unicenter trial for comparison of three regimens inde novo adult acute nonlymphoblastic leukaemia. Medical Oncology, 1998, 15, 183-190.	2.5	7
115	An artificial intelligent diagnostic system on differential recognition of hematopoietic cells from microscopic images. , 1997, 30, 145-150.		37